SAN DIEGO--(BUSINESS WIRE)--Mirador Therapeutics announced it has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301.
SAN DIEGO--(BUSINESS WIRE)--Mirador Therapeutics announced it has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301.
- Published
- Jul 16, 2026
- Updated
- Jul 16, 2026
- Source
- Businesswire
- Category
- Health
- Read time
- 1 min
Key facts
Key facts
Why this matters locally
This health story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.
Local impact
BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.
Timeline
PublishedJul 16, 2026, 2:18 PMThis story was published by BC Post.
ImportedJul 16, 2026, 6:01 PMThe item entered the BC Post source pipeline.
UpdatedJul 16, 2026, 6:01 PMThe article record or local context was updated.
Transparency
Source and credit
BC Post may summarize, organize, and add local context for reader clarity. Original reporting remains with the listed publisher.
Businesswire
Published Jul 16, 2026
Imported Jul 16, 2026
Read Original Source
Businesswire
Jul 16, 2026
Read Original Source
Related Articles
View all
Health
Study ties some birth control to brain tumours, but risks ‘rare’: experts
Health
Tactile Systems: Clean Balance Sheet, But A Possible Value Trap
Health
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
Health
The Surprising Cellular Benefit of the Pigment Behind Red Hair
More Local Coverage
Latest news
Politics
Powerful pro-life ad featuring boxing legend to air during final World Cup matches
Business
AI Market Trends: Q2 2026 Review and Forecast